Ide-Cel Treatment Associated With Greater Quality of Life Than Belantamab Mafodotin in R/R MM
Statistically significant differences were seen in global health status, pain, and fatigue.
Patients with relapsed/refractory multiple myeloma (MM) treated with idecabtagene vicleucel (ide-cel, Abecma, bluebird bio) in the phase 2 KarMMa study (NCT03361748) had higher health-related quality-of-life (HRQoL) scores than those treated with belantamab mafodotin (BM) in the DREAMM-2 study (NCT03525678).
These findings were presented at the European Hematology Association (EHA) 2022 Congress, June 9-12, held both virtually and in Vienna, Austria, by Nina Shah, MD, professor, Department of Medicine, University of California San Francisco.
“Although it has been demonstrated that clinical outcomes for patients treated with ide-cel were superior to those treated with BM, HRQoL outcomes have not been compared previously,” Shah and colleagues wrote.
Shah and colleagues analyzed data from 128 patients in the KarMMA study with a median follow-up of 15.4 months and 97 in the DREAMM-2 study with a median follow-up of 13.0 months. They used the nearest neighbor approach given differences in time points of evaluation between the 2 studies.
WATCH NOW: Frederick Locke, MD, on the Impact Potential of CAR T-Cell Therapies in Hematologic Malignancies
The investigators found that treatment with ide-cel was associated with improved HRQoL vs treatment with BM at all time points on the QLQ-C30 in global health status, pain, and fatigue both in naïve and Matching-Adjusted Indirect Comparison (MAIC)-adjusted analyses.
The mean difference in change from baseline was significant for global health status at all time points, with MAIC-adjusted 95% CIs of 8.71 (0.95-16.46) at 2 months, 14.78 (5.87-23.69) at 3 months, 16.53 (5.27-27.80) at 4 months, 19.33 (9.44-29.21) at 6 months, 21.76 (9.78-33.73) at 9 months, and 14.57 (0.82-28.21) at 12 months. Specifically, mean differences were statistically significant at 6 months in the fatigue domain, at 4, 6, and 9 months in QLQ-C30 pain domain and at 3, 4, and 6 months in the QLQ-MY20 pain domain. Additional sensitivity analyses according to covariates including high-risk cytogenetics and extramedullary disease confirmed results of the base analyses.
“Findings could be impacted by loss to follow-up; a smaller number of patients were evaluated at later time points in both KarMMA and DREAMM-2 versus earlier points... Overall these results suggest that one-time treatment with ide-cel offers improved HRQoL versus BM across the QLQ-C30 global health status/QoL, pain, and fatigue domains,” Shah and colleagues concluded.
To read more coverage of EHA 2022, click here.
